Please try another search
© Reuters. FILE PHOTO: A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. REUTERS/Dado Ruvic/Illustration
(Corrects share price to $47.67 from 447.67 in paragraph 2)
By Manas Mishra
(Reuters) - Pfizer Inc (NYSE:PFE) on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.
The U.S. drugmaker's shares rose 2.4% to $47.67 in morning trading as its third-quarter profit beat estimates, mainly due to better-than-expected sales of the vaccine.
The upbeat earnings also sent shares of rival COVID-19 vaccine makers higher. Novavax (NASDAQ:NVAX) Inc rose 11%, while Moderna (NASDAQ:MRNA) Inc gained about 4%.
Sales of the COVID-19 vaccine have eased from pandemic highs on soft demand for the original shots, sparking concerns over demand over the next few years.
In response, Pfizer plans to roughly quadruple the price of the vaccine, which it sells with German partner BioNTech, in the United States once the government stops buying doses and shifts to a private market.
"Our COVID-19 franchises will remain multi-billion-dollar revenue generators for the foreseeable future," Chief Executive Officer Albert Bourla said in prepared remarks ahead of a conference call.
Meanwhile, Pfizer is also expected to face the loss of patents for some key drugs between 2025 and 2030. The company has turned to deals such as its recent $5.4 billion acquisition of Global Blood Therapeutics (NASDAQ:GBT) Inc and its $11.6 billion purchase of Biohaven to beef up its pipeline.
While some will point to the massive Comirnaty beat as unsustainable, "we're not yet throwing in the towel given an emerging pipeline and significant balance sheet flexibility,", said BMO Capital Markets analyst Evan Seigerman.
Third-quarter sales of the COVID-19 vaccine came in at $4.40 billion, blowing past estimates of $2.60 billion.
However, $7.51 billion in sales of the company's COVID-19 pill Paxlovid missed estimates of $7.66 billion.
Pfizer earned $1.78 per share in the third quarter, beating estimates of $1.39.
Separately, the company said its experimental respiratory syncytial virus (RSV) vaccine was found to be effective in a late-stage study in preventing severe infections in infants when given to expectant mothers.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.